Affy 'Reassessing' Strategy, Focus after 'Challenging' Q2, New CEO Says
August 02, 2011
Affy 'Reassessing' Strategy, Focus after 'Challenging' Q2, New CEO Says
Acknowledging the challenges the firm faces and admitting it has been "slow to respond to technology changes" in the market, Frank Witney said the firm still has some opportunities to restore growth — if it positions its products correctly.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Affymetrix Restructures as Q3 Revenues Drop 14 Percent on Weak Product Sales
November 8, 2011 / BioArray News - Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News - Survey Offers 'Cautious Array Forecast' for Illumina as Sequencing, Affymetrix Products Gain Ground
April 16, 2013 / BioArray News - After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News - GeneSeek Sees 'Double-Digit' Growth in Demand for Agrigenomics SNP Array Services
January 29, 2013 / BioArray News